finance.yahoo.com ·
adaptive biotechnologies q1 earnings call 222314137
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedAdaptive Biotechnologies' strong MRD test volume and revenue growth indicate expanding clinical adoption of liquid biopsy for cancer monitoring. The company benefits from reimbursement tailwinds (Clinical Laboratory Fee Schedule) and partnerships (Pfizer). No direct scarcity or supply chain disruption; the mechanism is demand-driven revenue growth for a diagnostic service provider.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Q1 2026 revenue $70.9M, +45% YoY
- MRD revenue $67.1M, +53% YoY
- Record ~632,600 clonoSEQ tests in Q1
- Backlog ~$254M
- Full-year guidance raised to $260M–$270M
Mid-term revenue for clonoSEQ MRD testing expected to rise 2-4% over 1-4 weeks, with uncertainty in backlog conversion.
Sign in to see all sector verdicts, full thesis and counter-argument debate.